Akebia Therapeutics Inc
Company Profile
Business description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Contact
245 First Street
Suite 1400
CambridgeMA02142
USAT: +1 617 871-2098
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
181
Stocks News & Analysis
stocks
National Australia Bank earnings: Standing ground in business lending, but no earnings growth
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,950.18 | 124.05 | -1.54% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 323.90 | -0.68% |
| FTSE 100 | 9,646.00 | 89.78 | -0.92% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 23,004.54 | 495.26 | -2.11% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |